(Date:12/1/2009)...PRNewswire/ -- The Burrill Biotech Select Index ma...n October. The Select,s gain of 4.5 percent mirror...l markets with the Dow up 6.5 percent and the NASD... the final two trading days of the month despite i...y shopping and Dubai,s reported debt woes. ,, A...
(Date:12/1/2009)...nc. today announced a collaborative research agree... at evaluating EpiVax’s proprietary Tregitop...mental immune responses to certain drugs. In the c...x Tregitope technology will be evaluated for its e...ics. , (Vocus) December 2...
(Date:12/1/2009)... Palatin Technologies, In.... Patent and Trademark Office has issued U.S. Pate...de Constructs." The claims in the issued patent c...riuretic peptide receptor A (NPRA), including PL-3...,, "Our natriuretic compounds, including PL-399...
(Date:12/1/2009)...CH, California and AMSTERDAM, December 1 /PRNewswi... diagnostics, announced today that,Palmetto GBA, C...ablished,coding guidelines for the company,s Mamma...east cancer recurrence test, which has been reimbu...oss the United States can now submit claims for th...
Breaking Biology Technology:Biotech Gets Back on Track in November 2Biotech Gets Back on Track in November 3Biotech Gets Back on Track in November 4EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 2EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 3Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R) 2